{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:54:37Z","timestamp":1787500477916,"version":"build-2736575974"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pemphigus vegetans (PVeg) is a rare variant of pemphigus vulgaris characterized by pustules and\/or vegetating plaques, preferentially affecting the flexural areas. The diagnosis of PVeg depends on clinical grounds, histopathology, and direct immunofluorescence. Systemic corticosteroid is the first-line therapy for PVeg, and immunosuppressive treatments such as azathioprine, mycophenolate mofetil, and intravenous immunoglobulins can be used to improve remission rates. Also, there have been a few reports on the use of rituximab for treating PVeg. Here, we present a rare case of PVeg successfully treated by rituximab and provide the first brief review of the application of rituximab in PVeg. Additionally, this patient experienced muscle weakness after treatment but gradually improved with tapering prednisone, which increased our understanding of steroid myopathy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1701439","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:45:14Z","timestamp":1767599114000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pemphigus vegetans successfully treated with systemic corticosteroid and rituximab: a rare case report with 15-month follow-up and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongyan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03939.x","article-title":"Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study","volume":"25","author":"Zaraa","year":"2011","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2015.04.011","article-title":"Pemphigus vegetans of the folds (intertriginous areas)","volume":"33","author":"Ruocco","year":"2015","journal-title":"Clinics Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1374","article-title":"Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial","volume":"93","author":"Cao","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_688_2021","article-title":"Iatrogenic Kaposi\u2019s sarcoma induced by rituximab and corticosteroid treatment for pemphigus vegetans in an HIV-negative patient","volume":"88","author":"Daflaoui","year":"2022","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e13515","DOI":"10.1111\/dth.13515","article-title":"Pemphigus vegetans with paronychia-like changes resistant to rituximab therapy","volume":"33","author":"Ayoubi","year":"2020","journal-title":"Dermatol Ther"},{"key":"B7","article-title":"Treatment of pemphigus vegetans to rituximab refractory to conventional therapy","volume":"22","author":"Ruiz-Villaverde","year":"2014","journal-title":"Acta Dermatovenerol Croatica: ADC"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.11604\/pamj.2019.32.101.16743","article-title":"Unexpected positive outcome following rituximab treatment in a patient with pemphigus vegetans resistant to conventional therapies: a case report","volume":"32","author":"Barbach","year":"2019","journal-title":"Pan Afr Med J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000099591","article-title":"Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)","volume":"214","author":"Marzano","year":"2007","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12991","article-title":"Nonclassical pemphigus with exclusively IgG anti-desmocollin 3-specific antibodies","volume":"60","author":"Iranzo","year":"2019","journal-title":"Australas J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20149","article-title":"Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy","volume":"39","author":"He","year":"2025","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac398","article-title":"Adverse events of treatment with rituximab in patients with myositis","volume":"62","author":"Gilaberte","year":"2023","journal-title":"Rheumatol (Oxford England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1701439\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:45:16Z","timestamp":1767599116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1701439\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2025.1701439"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1701439","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1701439"}}